Ferroptosis
Description
Ferroptosis is a regulated form of non-apoptotic cell death driven by iron-dependent accumulation of lipid peroxides in cellular membranes. First defined by Brent Stockwell in 2012, the pathway is initiated when the glutathione-dependent enzyme GPX4 fails to neutralize lipid hydroperoxides, allowing unchecked oxidation of polyunsaturated fatty acids (PUFAs) in neuronal membranes. The brain is uniquely vulnerable due to its high PUFA content, high iron levels, and intense oxygen consumption.
In Alzheimer's disease, ferroptosis has emerged as a compelling cell death mechanism that links multiple established pathological features. Age-dependent iron accumulation in brain parenchyma fuels Fenton chemistry, generating hydroxyl radicals that attack membrane PUFAs. The toxic lipid aldehyde 4-HNE, a primary product of lipid peroxidation, covalently modifies and inhibits the lysosomal v-ATPase proton pump -- providing a direct biochemical bridge from oxidative membrane damage to autophagic collapse. FAD mutations in PSEN1 impair a Notch-LRP8-GPX4 signaling axis that normally sustains selenium uptake for GPX4 synthesis, creating a genetic link between presenilin biology and ferroptotic vulnerability.
Remarkably, both amyloid plaques and tau tangles may function as compensatory "sinks" that sequester toxic lipid aldehydes and redox-active iron, reframing these hallmark pathologies as initially protective responses to ferroptotic stress. The failure of the iron chelator deferiprone in clinical trials has challenged simplistic iron-removal strategies, suggesting the field must develop more nuanced anti-ferroptotic approaches.
Convergence Nodes
- Endosomal Nexus -- 4-HNE from ferroptotic lipid peroxidation poisons v-ATPase in endosomal-lysosomal compartments
- Compensatory Paradigm Nexus -- Amyloid and tau may serve as protective sinks for ferroptotic byproducts
- APOE4 Hub -- APOE4 loss of disulfide bridge leaves PUFA cargo unprotected against peroxidation
Prize Entrants
- Ashley Bush -- Proposed the Ferroptosis Theory of AD; identified the PSEN1-Notch-LRP8-GPX4 axis and APP-ferroportin iron efflux link
- Pamela Maher -- Developed the Oxytosis/Ferroptosis hypothesis; demonstrated 4-HNE inhibition of v-ATPase as the bridge to autophagic collapse; discovered geroneuroprotective compounds J147 and CMS121
External Scientists
- Brent Stockwell -- Defined ferroptosis as a distinct cell death mechanism; identified key molecular players including GPX4
- Scott Dixon -- Co-discovery of ferroptosis pathway
- Peng Lei -- Iron and ferroptosis in neurodegeneration
- Scott Ayton -- Brain iron accumulation and deferiprone clinical trial analysis
Key Open Questions
- Why did deferiprone worsen outcomes in AD patients -- is brain iron essential for certain neuroprotective functions?
- Can GPX4 activators or lipid peroxidation inhibitors be developed as targeted anti-ferroptotic therapies?
- Is ferroptosis the terminal cell death mechanism in AD, or does it intersect with necrosis and autophagic cell death?
- How does the 4-HNE-v-ATPase link interact with other v-ATPase inhibitory mechanisms (APP-betaCTF, gingipains)?
kb/wiki/concepts/ferroptosis.md